The US Congress has written to the National Institutes of Health (NIH) questioning the price Americans are charged for the prostate cancer drug Xtandi (enzalutamide) by Japanese company Astellas Pharma (TYO: 4503).
It has prompted a response over its efforts to make the drug accessible and affordable to men in the USA.
The letter, signed by 12 members of Congress, has asked the NIH to hold a public hearing on Xtandi to discuss how to address the issue of what it calls “excessive prices”.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze